BGA — BioNeutra Global Income Statement
0.000.00%
Last trade - 00:00
- CA$6.54m
- CA$12.85m
- CA$13.39m
- 47
- 76
- 43
- 55
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 37.7 | 37.7 | 24.1 | 15.4 | 13.4 |
Cost of Revenue | |||||
Gross Profit | 10.4 | 0.638 | 3.94 | 2.89 | 2.35 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 35.8 | 50.7 | 27.8 | 18.2 | 16.3 |
Operating Profit | 1.95 | -13 | -3.68 | -2.83 | -2.88 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 3.57 | -13 | -3.77 | -2.83 | -2.92 |
Provision for Income Taxes | |||||
Net Income After Taxes | 3.1 | -12.4 | -3.71 | -2.83 | -2.92 |
Net Income Before Extraordinary Items | |||||
Net Income | 3.1 | -12.4 | -3.71 | -2.83 | -2.92 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 3.1 | -12.4 | -3.71 | -2.83 | -2.92 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.065 | -0.244 | -0.074 | -0.061 | -0.062 |